ASCO accepts 375 abstracts of Sanofi-aventis
Monday, 11 June 2007
FE Report
A total of 375 abstracts on the oncology commitment of Sanofi-aventis have been accepted by the American Society of Clinical Oncology (ASCO) during its 43rd annual meeting held in Chicago, Illinois of the United States of America (USA) on June 1-5, said a press release.
The results from these key studies involving the company's leading anti-cancer agents, Eloxatin (oxaliplatin injection) and Taxotere (docetaxel injection concentrate), alongside clinical trial data examining investigational agents, aflibercept (VEGF-Trap), S-1 (oral fluoropyrimidine) and TroVax (therapeutic cancer vaccine) were presented in the conference which showed significant advances in the field of cancer treatment.
Eloxatin-FOLFOX4, an Eloxatin (oxaliplatin injection)- based chemotherapy regimen, significantly improved the overall survival (OS) of patients with surgically resected stage III colon cancer when compared to standard chemotherapy (5-FU/LV), according to the six-year survival analysis of the MOSAIC study presented at the meeting.
The updated analysis of the study's primary endpoint (3-year disease-free survival- DFS, including stage 11 and stage III patients) confirms the benefit of FOLFOX4 versus 5-FU/LV alone at 5 years.
Taxotere-based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial in HER2-positive MBC to evaluate efficacy and safety of Herceptin in combination with Taxotere (T) or Taxotere and Carboplatin (TC).
Aflibercept (VEGF-Trap) is an anti-angiogenic agent, which blocks the Vascular Endothelial Growth Factor (VEGF), and which is currently being investigated to assess its use in stopping tumour growth. Aflibercept is in phase III development as part of collaboration between Sanofi-aventis and Regeneron.
A total of 375 abstracts on the oncology commitment of Sanofi-aventis have been accepted by the American Society of Clinical Oncology (ASCO) during its 43rd annual meeting held in Chicago, Illinois of the United States of America (USA) on June 1-5, said a press release.
The results from these key studies involving the company's leading anti-cancer agents, Eloxatin (oxaliplatin injection) and Taxotere (docetaxel injection concentrate), alongside clinical trial data examining investigational agents, aflibercept (VEGF-Trap), S-1 (oral fluoropyrimidine) and TroVax (therapeutic cancer vaccine) were presented in the conference which showed significant advances in the field of cancer treatment.
Eloxatin-FOLFOX4, an Eloxatin (oxaliplatin injection)- based chemotherapy regimen, significantly improved the overall survival (OS) of patients with surgically resected stage III colon cancer when compared to standard chemotherapy (5-FU/LV), according to the six-year survival analysis of the MOSAIC study presented at the meeting.
The updated analysis of the study's primary endpoint (3-year disease-free survival- DFS, including stage 11 and stage III patients) confirms the benefit of FOLFOX4 versus 5-FU/LV alone at 5 years.
Taxotere-based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial in HER2-positive MBC to evaluate efficacy and safety of Herceptin in combination with Taxotere (T) or Taxotere and Carboplatin (TC).
Aflibercept (VEGF-Trap) is an anti-angiogenic agent, which blocks the Vascular Endothelial Growth Factor (VEGF), and which is currently being investigated to assess its use in stopping tumour growth. Aflibercept is in phase III development as part of collaboration between Sanofi-aventis and Regeneron.